{"classes":[{"categories":[{"measurements":[{"comment":"Here, \"NA\" indicates that lower and upper limit of 90% confidential interval (CI) was not estimable because no participants had the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria was defined as: less than 5 percent (%) blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets greater than (\\>)100\\*10\\^9 cells/liter (L) and absolute neutrophil count (ANC) \\>1.0\\*10\\^9 cells/L. This outcome measure was planned to be analyzed for specified arm only.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory B-cell ALL received intrathecal methotrexate (MTX) 8 milligrams (mg): 1 to less than (\\<) 2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: greater than or equal to (\\>=) 9 years on Cycle 1 Day 1 (for all participants) and Cycle 2 and later Day 1 each Cycle (for CNS negative participants); for CNS positive participants: along with MTX, hydrocortisone (HC)/cytarabine (ARA-C) was administered per local standard practice; daratumumab 16 milligrams per kilogram (mg/kg) as intravenous (IV) infusion weekly on Days 1, 8, 15 and 22 of Cycles 1 and 2 then every 2 weeks on Days 1, 15 of Cycle 3 to 6 and every 4 weeks on Day 1 of Cycle 7 and onward; vincristine 1.5 milligrams per meter square (mg/m\\^2) IV injection/infusion once weekly on Days 1, 8, 15 and 22 of Cycle 1, then every 2 weeks on Days 1 and 15 of Cycle 2 and every 4 weeks on Day 1 of Cycle 3 and onward; prednisone 40 mg/m\\^2 orally daily on Day 1 to 28 of Cycle 1 and on Day 1 to 5 of Cycle 2 onward. Participants received treatment until disease progression, unacceptable toxicity, or proceeding hematopoietic stem cell transplant after complete response (CR), whichever came first (maximum duration: 2.3 months).","id":"OG000","title":"Cohort 1: B-cell ALL (1-17 Years)"}],"paramType":"NUMBER","populationDescription":"The all treated analysis set included all enrolled participants who received at least 1 dose of daratumumab.","reportingStatus":"POSTED","timeFrame":"Up to 2 cycles, that is, up to 56 days (each cycle of 28-days)","title":"Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}